```html

Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life‑threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the microvasculature. These clots consume platelets, leading to a low platelet count (thrombocytopenia) and cause blockage of blood flow to vital organs.

There are two major forms:

• Acquired (immune‑mediated) TTP – caused by auto‑antibodies that inhibit the enzyme ADAMTS13.
Hereditary (congenital) TTP – caused by genetic mutations that reduce ADAMTS13 production.

Who it affects: TTP most commonly presents in adults aged 30–50, but it can occur at any age, including in children (especially the hereditary form). Women are slightly more affected than men (approximately 1.5:1 ratio) [1].

Prevalence: The annual incidence is about 3–4 cases per million persons in the United States and Europe [2]. Because of its rarity, many clinicians may encounter it only once in their career, underscoring the need for heightened awareness.

Symptoms

The classic pentad described in textbooks (fever, neurological changes, renal dysfunction, microangiopathic hemolytic anemia, and thrombocytopenia) is now known to occur in only a minority of patients. Early symptoms are often nonspecific, which can delay diagnosis.

Core symptoms (present in >80% of patients)

• Fatigue and weakness – due to anemia and low platelet count.
• Bruising or petechiae – tiny red or purple spots on skin caused by bleeding under the skin.
• Purpura – larger areas of bleeding that may look like bruises.
• Neurologic changes – confusion, headaches, visual disturbances, seizures, or transient ischemic attacks.
• Renal involvement – mild to moderate rise in creatinine, hematuria, or proteinuria.

Additional symptoms

• Fever (often low‑grade)
• Gastrointestinal upset – nausea, vomiting, abdominal pain.
• Jaundice – from rapid breakdown of red blood cells.
• Shortness of breath – if micro‑clots affect the lungs.

Because symptoms evolve quickly—often within hours to days—any combination of the above in a previously healthy individual should raise suspicion for TTP.

Causes and Risk Factors

TTP results from a severe deficiency (<10% of normal) of the metalloprotease ADAMTS13, which normally cleaves ultra‑large von Willebrand factor (vWF) multimers. Lack of ADAMTS13 allows vWF to aggregate platelets, forming clots.

Acquired (immune‑mediated) TTP

• Auto‑antibodies targeting ADAMTS13 (most common cause).
• Associated conditions:
  • Systemic lupus erythematosus (SLE)
  • HIV infection
  • Malignancies (especially solid tumors)
  • Pregnancy and postpartum period (particularly in the 3rd trimester)
  • Medications: quinine, ticlopidine, clopidogrel, cyclosporine, certain chemotherapeutics.

Hereditary (congenital) TTP

• Autosomal recessive mutations in the ADAMTS13 gene.
• Often diagnosed in infancy or early childhood, but milder mutations may present later.

Risk factors

• Female gender (especially during pregnancy).
• Previous episode of TTP – recurrence risk is ~30% within 5 years [3].
• Underlying autoimmune disease.
• Recent viral illness (e.g., influenza, COVID‑19) – likely due to immune activation.

Diagnosis

Prompt diagnosis is essential; treatment should begin on clinical suspicion while laboratory confirmation is pending.

Initial laboratory evaluation

• Complete blood count (CBC) – low platelets (<30 × 10⁹/L) and anemia with schistocytes on peripheral smear.
• Peripheral blood smear – presence of fragmented RBCs (schistocytes) confirming microangiopathic hemolytic anemia.
• LDH (lactate dehydrogenase) – markedly elevated due to cell destruction.
• Haptoglobin – low/undetectable.
• Creatinine & BUN – assess renal function; may be mildly elevated.
• Coagulation panel (PT/INR, aPTT) – usually normal, helping differentiate from DIC.
• Urinalysis – hematuria or proteinuria.

Specific ADAMTS13 testing

• ADAMTS13 activity assay – activity <10% is highly suggestive of TTP.
• ADAMTS13 inhibitor test – detects auto‑antibodies; positive in acquired TTP.
• These results may take days; clinicians often use scoring systems (e.g., PLASMIC score) to estimate probability while awaiting results [4].

Imaging (when indicated)

• CT or MRI of brain if focal neurologic deficits are present.
• Renal ultrasound if significant renal impairment.

Treatment Options

Therapy aims to restore ADAMTS13 activity, stop micro‑thrombosis, and prevent organ damage. Early treatment dramatically reduces mortality—from >90% historically to <10% today [5].

First‑line therapy

• Therapeutic plasma exchange (TPE) – daily exchange of 1–1.5 plasma volumes with fresh frozen plasma (FFP) or solvent/detergent‑treated plasma. Removes inhibitory antibodies and supplies functional ADAMTS13.
• Adjunctive corticosteroids – e.g., methylprednisolone 1 mg/kg IV daily, then taper; dampens autoimmune response.

Targeted immunotherapy

• Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; especially useful in refractory or relapsing cases and in patients with high inhibitor titers.
• Caplacizumab – a nanobody that blocks vWF‑platelet interaction. Given as a 10 mg IV bolus before first plasma exchange, then 10 mg subcutaneously daily until 30 days after the last TPE. Clinical trials showed faster platelet recovery and reduced relapse rates [6].

Supportive care

• Transfusion of red blood cells for symptomatic anemia.
• Avoid platelet transfusions unless life‑threatening bleeding occurs, as they may worsen thrombosis.
• Renal replacement therapy if acute kidney injury progresses.
• Antiepileptic drugs if seizures develop.

Management of hereditary TTP

• Regular prophylactic plasma infusions (15–20 mL/kg) every 2–3 weeks to maintain ADAMTS13 activity.
• Emerging gene‑therapy approaches (e.g., adeno‑associated virus vector delivering ADAMTS13) are under investigation in clinical trials.

Living with Thrombotic Thrombocytopenic Purpura

Even after remission, patients often need lifelong follow‑up.

Follow‑up schedule

• First month: weekly CBC, LDH, and renal panel.
• Months 2–6: bi‑weekly to monthly labs.
• Thereafter: every 3–6 months, or sooner if symptoms recur.

Medication adherence

• Continue any immunosuppressive agents (e.g., low‑dose prednisone, rituximab maintenance) as prescribed.
• If on caplacizumab, adhere to the post‑exchange dosing schedule to prevent rebound.

Lifestyle tips

• Hydration – maintain adequate fluid intake to support renal function.
• Avoid triggers – limit alcohol, refrain from quinine‑containing medications, discuss new drugs with your hematologist.
• Vaccinations – stay up to date, especially influenza and COVID‑19, to reduce infection‑related relapses.
• Pregnancy planning – coordinate care with a maternal‑fetal medicine specialist; TTP can recur during pregnancy.
• Stress management – chronic stress may influence immune activity; consider counseling, yoga, or meditation.

Psychosocial support

Living with a rare, potentially fatal disease can be anxiety‑provoking. Access to patient support groups (e.g., TTP Advocacy, National Hemophilia Foundation) and mental‑health professionals is recommended.

Prevention

Because many cases are immune‑mediated, absolute primary prevention is challenging. However, the following strategies can lower risk of relapse:

• Adhere to maintenance immunosuppression (rituximab, mycophenolate) if prescribed.
• Promptly treat infections; seek medical care for fevers or flu‑like illnesses.
• Avoid known drug triggers (quinine, certain antiplatelet agents) and discuss any new prescription with your hematologist.
• Regular laboratory monitoring to catch asymptomatic drops in platelet count or rising LDH early.

Complications

If TTP is untreated or delayed, micro‑thrombi can cause irreversible organ injury.

• Neurologic damage – stroke, seizures, persistent cognitive deficits.
• Renal failure – acute tubular necrosis leading to chronic kidney disease.
• Cardiac ischemia – myocardial infarction from coronary micro‑thrombosis.
• Hemorrhage – intracranial or gastrointestinal bleeding due to severe thrombocytopenia.
• Relapse – up to 30% of acquired TTP patients experience at least one recurrence.
• Death – historically >90% mortality; modern therapy reduces this to <10% but risk persists in refractory disease.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Thrombotic thrombocytopenic purpura (TTP).” Updated 2023. https://www.mayoclinic.org/diseases-conditions/tTP
2. CDC. “Rare Blood Disorders: TTP.” 2022. https://www.cdc.gov/ncbddd/tp
3. George JN, Nester CM. “Spear’s Review of Hematology.” 8th ed., 2023.
4. Sadler JE. “The PLASMIC score: a practical tool for rapid identification of TTP.” Blood. 2020;136(6):735‑743.
5. Joly BS, et al. “Outcomes of thrombotic thrombocytopenic purpura in the modern era.” Blood Advances. 2021;5(14):3655‑3665.
6. Scully M, et al. “Caplacizumab treatment for acquired TTP: results from the HERCULES trial.” NEJM. 2019;380:335‑346.

```